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Abstract
The Sa system is a recently described immune system that has a specificity and positive
predictive value of nearly 100% for rheumatoid arthritis (RA) in Asia, Europe and the
Americas. Its sensitivity of 30–40% suggests that it identifies a subset of RA patients. Anti-
Sa antibodies are present from disease onset and are predictive of disease severity. The
immune reactants are plentiful in the target tissue: antigen is present in the synovium, IgG
antibody in the fluid. Immunologically, Sa is a hapten-carrier antigen in which vimentin is the
carrier and citrulline is the hapten. The citrullination of vimentin is closely related to
apoptosis, and citrullinated vimentin is extremely sensitive to digestion by the ubiquitous
calpains. Nevertheless, Sa is found in only a few cell lines. Calpastatin, the natural specific
inhibitor of calpains, is also a RA-associated, albeit non-specific, autoimmune system. Is it
possible that calpain-related apoptotic pathways could be prominent in cells containing Sa?
The task is to reconcile the specificity of Sa/citrullinated proteins in a multifactorial and
polygenic disease such as RA.
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Introduction
The objective of current research activity on RA-associ-
ated autoimmune systems is to find a disease-specific
marker [1]. It would be simplistic to view that marker as
being primarily of importance in clinical diagnosis. Indeed,
its net diagnostic contribution beyond that of using the
American College of Rheumatology (ACR) criteria with
rheumatoid factor is likely to be clinically insignificant in
established RA [2–4]. What clinicians really need is a
marker that would be a good a priori predictor of future
disease severity [5]. In contrast, what researchers are
looking for are fresh etiopathogenic clues [6].
Sa for the clinician
The serum of Mrs Sa… identifies unique tissue-specific
banding patterns at approximately 50kDa in western blots
with normal human spleen and placenta, and rheumatoid
synovial extracts [7–9]. Until recently (see below), the Sa
polypeptides were not found in extracts of a variety of cells
of different lineage and were different in western blots
from all previously described systems associated with RA
including rheumatoid factor, filaggrin and calpastatin
[7,9,10]. The components of the Sa system are present at
high concentrations in the rheumatoid joint: antigen in the
synovium and IgG antibody in the fluid [8,11]. Looking forArthritis Research    Vol 2 No 6 Ménard et al
autoantibodies in sera of 20 pairs of monozygotic twins
discordant for RA, anti-Sa antibodies were found only in
rheumatoid twins, whereas all the previously mentioned
autoantibodies could be found in both rheumatoid and
healthy twins [12]. A caveat to that study is the fact that
we could test only those sera with the immunofluores-
cence method for anti-perinuclear factor (APF) and anti-
keratin antibodies (AKA). Both tests are plagued with
problems of subjective interpretation. The possibility there-
fore cannot be excluded that our observation could be
extended to antibodies against other citrullinated protein
or peptide antigens if properly assayed (see below).
Overall, those results suggest a closer association of anti-
Sa with the disease than with the genes [12]. That last
piece of information supports the hypothesis of an envi-
ronmental trigger.
To submit patients to early aggressive therapy, candidate
markers are needed that are both present at disease onset
and predictive of disease severity. The shared epitopes of
human leucocyte antigen (HLA)-DR alleles have provided
epidemiological insight in our understanding of RA but
have proved to be of little utility in the clinic because
shared epitope genotyping is essentially an a posteriori
marker of disease severity [3,13–15]. In contrast, the anti-
Sa antibody is present in early disease [4,7,16] and
seems to be slightly better than HLA genotyping and other
autoantibodies as a predictor of ‘erosivity’ [3,4]. The anti-
Sa antibody sensitivity (approximately 43%), specificity
(approximately 99%) and positive predictive value (approx-
imately 97%) for RA have been remarkably reproducible in
more than 3000 patients from Europe, America and Asia
[3,4,7,16–18] (Table 1).
Sa for the researcher
In the past 10 years we have purified Sa from human pla-
centa and obtained several amino acid microsequences
that all pointed to vimentin as the elusive Sa antigen
[15,17]. That was in flagrant contradiction of all the pub-
lished work on anti-vimentin autoantibodies in human dis-
eases and with the observed RA specificity. All our efforts
at cloning Sa with affinity-purified and IgG-adsorbed
rheumatoid anti-Sa antibodies to immunoscreen human
placental cDNA expression libraries were unsuccessful.
As a by-product, we cloned the RA-associated autoanti-
gen, calpastatin (see below) [16]. We were even unable
to clone vimentin. We were obviously missing something.
Interestingly, the Sa and citrulline-related autoimmune
systems (anti-perinuclear-APF, anti-profilaggrin-APF, anti-
keratin-AKA, anti-filaggrin-AFA and anti-citrullinated pep-
tides-ACP antibodies) have the same high specificity for
RA and early predictive potential for severe RA [3,4,
19–21]. The explanatory breakthrough came from the
recent research on filaggrin.
Sa and filaggrin are two different proteins that are both
specifically and often (but not always) simultaneously tar-
geted by the same RA sera [3]. A survey of the metabolic
handling of filaggrin reveals that it is dephosphorylated,
deiminated and twice proteolytically cleaved by enzymes,
the latter step being by means of the calcium-dependent
cytosolic calpains [1,22–25]. The identification of the cit-
rulline epitopes responsible for the reactivity of RA sera
with filaggrin was therefore a logical and major step
forward [19,20]. The epitopes are centered on citrulline
residues resulting from the deimination of selected arginine
residues on filaggrin. That post-translational modification is
performed by the calcium-dependent peptidylarginine
deiminase (PAD) present in the skin. There are at least four
other PAD isoenzymes in other tissues (data from
GenBank). We recently identified by western blot an
Sa-related, disease-specific, complex banding pattern in
ECV 304, a human endothelial cell line, and in human
umbilical-vein endothelial cells. Exactly the same multiplicity
Table 1
Diagnostic significance of anti-Sa in the rheumatic diseases
Total no. Rheumatoid Positive predictive
Country Reference of patients patients Sensitivity (%) Specificity (%) value (%)
Canada [7] 482 206 43 99 97
Spain [17] 1087 360 33 100 99
France [3] 403 154 40 92 n/a
Austria [16] 247 46 37 98 n/a
China [18] 518 191 32 99 94
Total 2737 957 37 98 97
The control populations were normal individuals and patients with degenerative arthritis from the communities shown, autoimmune patients with
systemic lupus erythematosus, Sjögren and other systemic connective tissue diseases, and patients with chronic arthritis of the spondylarthropathy
variants. All RA patients satisfied the ACR criteria, including those with early (less than 1 year) disease. It is important to note that the data on
sensitivity, specificity and positive predictive value for RA are valid only for established RA cohorts and would not necessarily apply to early
synovitis cohorts, where satisfying the ACR criteria for RA at entry is not a prerequisite. n/a, not applicable.http://arthritis-research.com/content/2/6/429
of the reaction was seen with a rabbit polyclonal anti-cit-
rulline antibody [26]. We extended that observation to
show that bovine albumin, total histones and myelin basic
protein could all serve as a carrier of the RA-specific epi-
topes when they were citrullinated in vitro with PAD [27].
We have since cloned vimentin by PCR and citrullinated its
expressed recombinant in vitro. By differential absorption it
proved to be the Sa antigen (Lapointe E, Rochdi MD,
Ménard HA, in preparation). Trichohyalin (APF), filaggrin
(AFA), keratin (AKA), vimentin (anti-Sa), myelin basic
protein and fibrin [28] are all citrullinated in vivo. All those
proteins can also be citrullinated in vitro and function as
RA-specific targets, albeit with different sensitivity. The clin-
ical and pathophysiological significance of that phenome-
non does not seem to be important in vivo, at least in the
skin or nervous system in RA. It might be important if the
carrier-hapten is generated and accessible to the adaptive
immune system in the articular tissues.
Future research on Sa
Our working hypothesis is that Sa or citrullinated vimentin
is the original hapten-carrier immunogen. Classically,
antigen-presenting cells will process the original carrier
and present its derived peptide in an MHC-restricted
fashion at the T cell level and carrier-specific help will then
be provided to the hapten-specific B cell. Although the
original carrier is important in vivo, the carrier is not impor-
tant in detecting anti-hapten antibodies in vitro. That
explains why apparently entirely different RA-specific
humoral systems were found independently. Many ques-
tions now arise, of which the following are a sample. How
does citrullination of specific arginine residues come
about? Are there cell-specific PADs? How many different
PADs are there in each cell type? Vimentin is preferentially
citrullinated during apoptosis; that results in protein denat-
uration and the disorganization of intermediate filaments
[29,30]. However, although vimentin is untouched, Sa or
citrullinated vimentin is destroyed almost immediately in
vitro by calpains [17]. Why can it survive as a molecule
only in certain cells such as endothelial cells? Where else
can it survive? Is that related to its immunogenicity and
why? Why is vimentin not co-targeted more often in RA?
Is the RA-associated secondary development of antibod-
ies against calpastatin, the natural inhibitor of calpains, a
related defence mechanism or a pro-inflammatory amplifi-
cation loop [31]? Is the extraordinary fine disease speci-
ficity of the autoantibodies representing the mythical
footprint of the elusive initial causative event(s)? Indeed,
several microorganisms have arginine-to-citrulline deimi-
nase activities. Can they also citrullinate proteins? Such a
post-translational modification coming from the environ-
ment would be a fresh illustration of the ‘hit-and-run’
theory of autoimmunity.
In autoimmune diseases, ‘multifactorial’ and ‘polygenic’ are
vogue words. ‘Multifactorial’ could mean the assault of
non-specific environmental factors acting preferentially on
specific cells or tissues. That would result in the overpro-
duction of specific endogenous or exogenous arginine
deiminases with the over-citrullination or under-citrullina-
tion of residues normally or not normally modified by that
post-translational pathway. Because citrullination, whether
by means of apoptosis or by some other mechanism, is a
natural phenomenon, those neo-antigens would need to
occur in individuals with the appropriate polygenic back-
ground (30 or so genes, as in lupus) that would modulate
apoptosis, break tolerance, mount the specific immune
response and influence disease expression. Exploring that
framework will probably earn great dividends for both
patients and science.
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